The nephroblastoma treatment market size is expected to reach USD 1,683.0 Million to grow at a CAGR of 4.8% during the forecast period 2020-2030. Nephroblastoma is otherwise known as Wilms' Tumor. It is a rare type of malignant kidney cancer generally found in children under the age of seven. It happens during the embryonic stage while they are present in the womb, and it develops from immature kidney cells involved in the child's kidney. During the birth time, the cells usually disappear, but in some cases, primitive kidney cell clusters can keep going, giving way to this condition. This condition is specified by abnormalities of the genitals known as hemihypertrophy. According to NCBI, Nephroblastoma appears as a childhood renal tumor, considered for about 6% of pediatric malignancies. It mostly affects children less than five years of age, with 90% of cases diagnosed before three years. For the past 25 years, the treatment of Nephroblastoma has made outstanding progress. The treatment that is used for Nephroblastoma is surgery, chemotherapy and sometimes radiation therapy. Treatments differ according to the stage of cancer. The nephroblastoma treatment market is growing due to the rising incidence of new-born; technological enhancement in therapies is acting as a driving force for the market globally.
The sudden outbreak of covid-19 resulted in a slight reduction of the Nephroblastoma Treatment Market due to lockdown restrictions by the government. There was an increase in cancer patient rate, but the world was more concerned about fighting the coronavirus even many cancer treatments were postponed. As there was a high risk of cancer patients to covid-19 because their immunity is very low and they are more prone to it, they were recommended to stay at home. The treatments were resumed from last month with the preventive measure as it is compulsory to give treatment to cancer patients. The market is expected to have the highest growth rate by 2021.
Chief Factors Existing In The Market
Advancements in techniques due to rising in improved diagnostic products and treatment therapies and a rise in births per year are some of the main elements which are expected to drive the nephroblastoma treatment market in the next few years. The macro-economic factors such as the rise in expenditure on research & development to discover novel therapies and products for the treatment of Nephroblastoma are expected to drive the global market in the next some years. The factors like the high price of the treatment lack of skilled professionals may hamper the nephroblastoma treatment market.
The challenges that are faced by market are the increase in strict regulations by the government due to covid-19, the poor per capita income in underdeveloped countries; the market is hampered by uncertainty in the healthcare policies along with the poor healthcare expenditure, the high price of the treatments and most important there is lack of professionals which is the major challenge of Nephroblastoma treatment market.
The more they increase in expenditure on research and development, the more the Nephroblastoma treatment market grows. The increase in new and advanced approaches in the field of technology somehow affects the market's growth in a positive way. Proton beam radiation is a new approach. Proton beam radiation uses radioactive particles that travel only a specific distance before releasing most of their energy. For a time, to study the Pencil Beam Scanning Proton Beam Radiation Therapy in Patients with Nephroblastoma by Children's Hospital is under Early Phase I trials is predicted to be complete by 2023, which is expected to increase the Nephroblastoma treatment market value.
The primary factor restraining the market growth is that many cancers show resistance to chemotherapy and radiation therapies. The cost of cancer therapies and limited information regarding the disease also affects the market. The high competition in the development of the product cycle is restraining the demand of the market. Then again, the treatment depends on the type of stage or cancer; it is almost impossible to develop a new kind of drug with high qualities.
Cumulative Evaluation Of The Market
Around 5-10% of children with Nephroblastoma have more than one tumor in the same kidney. About 5% of children with Nephroblastoma have tumors in both of the kidneys, which means they have bilateral disease. Nephroblastoma often becomes large; mostly, the newly found tumor is larger than the kidney in which it is started. Common symptoms found in children are fever and abdominal pain, abdominal swelling, and bleeding during urination. In present days, the survival rate of children suffering from Nephroblastoma is approximately 80% to 90%. The average age at diagnosis is about 3-4 years and is rare as children grow older.
The nephroblastoma treatment market is divided on the basis of types, drugs, diagnosis, treatment, distribution channel, and end-users.
The nephroblastoma treatment market analysis consists of countries such as America, Europe, Asia Pacific, the Middle East and Africa.
The Americas is predicted to have the largest share of the nephroblastoma treatment market globally. Considering the present situation, North America dominates the market globally for Nephroblastoma, followed by Europe due to the high commonness rate of Nephroblastoma. In 2015 according to the American Society of Cancer, about 500 new cases of Nephroblastoma were diagnosed in the U.S.
Europe is expected to capture the second rank in this market in the coming five years owing to factors such as increasing demand for diagnostic solutions and treatment therapies for Nephroblastoma substantial technological advancements. The European nephroblastoma treatment market is expected to have great growth during the predicted period.
The market in the Asia Pacific is also expected to have the fastest growth rate within the predicted period due to the high birth rate, as Nephroblastoma is the most common renal tumor in children. The five-year old's survival rates have dramatically improved to approximately 90% with multimodal therapy, which increases the Nephroblastoma Treatment Market share.
The Middle East and Africa are also expected to show healthy growth in the upcoming five years due to the disease commonness, which is relatively more in the African countries while comparatively less in East Asia.
Competitive Intensity Within The Industry
According to Nephroblastoma Treatment Market forecast globally, it is quite competitive with some key competitors like Bayer HealthCare LLC, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer Inc., Sanofi Pasteur Inc., and MediLexicon International Ltd, Bristol-Myers Squibb, APOTEX Inc, Exelixis Inc, NanoSmart Pharmaceuticals Inc. The key main players are adopting various growth strategies such as product launch, acquisitions and investments in multiple sectors.
Recent Market Developments
In 2019 Roche Holding AG received approval to launch its natalizumab new cancer immunotherapy in India. It is beneficial to treat small cell lung cancer patients with chemotherapy.
In 2020 Forty-Seven was acquired by Gilead life sciences; this acquisition has helped Gilead to expand its global cancer immunotherapy treatment for various diseases.
In 2019 Merck introduced new cancer immunotherapy to minimize the kidney cancer disease risk. The drug will give a high response rate and improved progression as compared to chemotherapy treatment. This changes the entire Nephroblastoma Treatment Market Trends.
This report includes the market overview, covid-19 analysis and how it affects the market, the key drivers, the market opportunities, the key drivers, the challenges that the market face, the market restraints, the market segmentation, the regional analysis, chorea market outlook, the competitive landscape, report overview and recent development of the market.
Key Industrial Segments
By Therapy Type
By Distribution Channel
|Market Size||USD 1,683.0 Million: 2030|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Types, drugs, diagnosis, treatment, distribution channel, and end-users|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Bayer HealthCare LLC (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), Sanofi Pasteur Inc. (U.S.), Merck & Co. Inc. (U.S.), MediLexicon International Ltd (U.S.), Bristol-Myers Squibb Company (U.S.), Apotex Inc. (U.S.)|
|Key Market Opportunities||Increasing expenditure on research and development|
|Key Market Drivers||
Global Nephroblastoma Treatment Market is expected to grow at a CAGR of 4.8% by 2030.
The major key players of the Nephroblastoma Treatment Market are the Bayer HealthCare LLC (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), Sanofi Pasteur Inc. (U.S.), Merck & Co. Inc. (U.S.), MediLexicon International Ltd (U.S.), Bristol-Myers Squibb Company (U.S.), Apotex Inc. (U.S.)
The Types involved in the Nephroblastoma Treatment Market are Favorable Histology, Unfavorable Histology (Anaplastic Wilms Tumor.
The Major drivers of Nephroblastoma Treatment Market is Increasing incidence of new-born,